Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.75
USD
|
+2.34%
|
|
+8.70%
|
-43.55%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,754
|
1,048
|
397.3
|
158.6
|
90.03
|
-
|
-
|
Enterprise Value (EV)
1 |
2,393
|
751.1
|
289
|
120.9
|
-320.9
|
-201.4
|
-365.6
|
P/E ratio
|
-25.6
x
|
-18
x
|
-5.4
x
|
-2.15
x
|
-1.21
x
|
-1.18
x
|
-1.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
30.8
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-125
x
|
EV / EBITDA
|
-69.1
x
|
-13
x
|
-3.77
x
|
-1.53
x
|
3.01
x
|
1.5
x
|
2.31
x
|
EV / FCF
|
-72.8
x
|
-
|
-
|
-
|
5.01
x
|
2.96
x
|
3.83
x
|
FCF Yield
|
-1.37%
|
-
|
-
|
-
|
19.9%
|
33.8%
|
26.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
44,774
|
45,380
|
45,665
|
51,158
|
51,443
|
-
|
-
|
Reference price
2 |
61.51
|
23.10
|
8.700
|
3.100
|
1.750
|
1.750
|
1.750
|
Announcement Date
|
3/3/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.925
|
EBITDA
1 |
-
|
-34.62
|
-57.99
|
-76.72
|
-78.88
|
-106.8
|
-134.5
|
-158.1
|
EBIT
1 |
-
|
-34.94
|
-58.29
|
-77.04
|
-80.13
|
-83.6
|
-95.28
|
-105.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,617.96%
|
Earnings before Tax (EBT)
1 |
-
|
-34.43
|
-57.82
|
-73.33
|
-68.96
|
-73.02
|
-81
|
-77.88
|
Net income
1 |
-25.35
|
-34.44
|
-57.85
|
-73.32
|
-68.96
|
-73.02
|
-81
|
-77.88
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,662.6%
|
EPS
2 |
-8.372
|
-2.400
|
-1.280
|
-1.610
|
-1.440
|
-1.442
|
-1.478
|
-1.130
|
Free Cash Flow
1 |
-
|
-32.89
|
-
|
-
|
-
|
-64
|
-68
|
-95.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,264.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/26/20
|
3/3/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-18.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.1
|
-18.47
|
-18.62
|
-17.88
|
-19.38
|
-21.16
|
-21.48
|
-20.12
|
-19.63
|
-18.9
|
-19.87
|
-20.71
|
-21.6
|
-21.44
|
-25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.99
|
-18.36
|
-18.43
|
-17.31
|
-18.24
|
-19.34
|
-19.13
|
-17.43
|
-16.64
|
-15.76
|
-17.1
|
-18.07
|
-18.61
|
-19.26
|
-25.02
|
Net income
1 |
-15.01
|
-18.36
|
-18.43
|
-17.31
|
-18.23
|
-19.34
|
-19.13
|
-17.44
|
-16.64
|
-15.76
|
-17.1
|
-18.07
|
-18.61
|
-19.26
|
-25.02
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3300
|
-0.4000
|
-0.4100
|
-0.3800
|
-0.4000
|
-0.4300
|
-0.4200
|
-0.3800
|
-0.3400
|
-0.3100
|
-0.3400
|
-0.3540
|
-0.3620
|
-0.3760
|
-0.4900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/1/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/1/23
|
5/10/23
|
8/9/23
|
11/9/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
361
|
297
|
108
|
37.7
|
411
|
291
|
456
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-32.9
|
-
|
-
|
-
|
-64
|
-68
|
-95.5
|
ROE (net income / shareholders' equity)
|
-
|
-15.1%
|
-17.3%
|
-26.4%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-2.280
|
-1.030
|
-1.400
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.15
|
-
|
-
|
0.96
|
-
|
2.29
|
39.6
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,354.36%
|
Announcement Date
|
6/26/20
|
3/3/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
1.75
USD Average target price
5.667
USD Spread / Average Target +223.81% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.55% | 90.03M | | +1.51% | 42.75B | | +48.09% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|